Group A Meningococcal Polysaccharide Vaccine DiluentA群脑膜炎球菌多糖疫苗稀释液

This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。

Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。

生产企业Manufacturer

主要成分Active Ingredients

药物知识说明

经提取获得的荚膜多糖抗原是一种在国家药监局注册认定的药品。该药品含有相关活性成分。

该药品关联的活性成分包括:经提取获得的荚膜多糖抗原Jingti Quhuo Dede Jiamo Duotang Kangyuan。这些成分信息来自国家药监局数据库。

您可以探索含有相同成分的其他药品:经提取获得的荚膜多糖抗原-a4118ab5成分药品。

本页面内容来自国家药监局数据库,MedicineGraph在此基础上提供关系图谱和知识导航。

Medicine Knowledge

This medicine (original name: A群脑膜炎球菌多糖疫苗稀释液) is a medicine registered with the national drug regulatory authority. It contains active ingredient(s) as recorded.

Active ingredients associated with this product: 经提取获得的荚膜多糖抗原Jingti Quhuo Dede Jiamo Duotang Kangyuan.

Explore other medicines containing the same ingredient: 经提取获得的荚膜多糖抗原 productsProducts containing this recorded ingredient.

Source: MedicineGraph authoritative database. Relationships derived from registered product information.

这是什么What is this

  • 通用名/品名Recorded product name: A群脑膜炎球菌多糖疫苗稀释液Group A Meningococcal Polysaccharide Vaccine Diluent
  • 规格Specification: 5ml5 mL

本段仅展示注册/说明书已记录的身份属性,不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.

主要成分Ingredients

生产企业Manufacturer

  • 上海生物制品研究所有限责任公司Shanghai Shengwu Zhipin Yanjiu Suoyou Xianze Rengong Si

注册信息NMPA approval number

  • 批准文号NMPA approval number: 国药准字S10850047

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.

  • 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
  • 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.

本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.

English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.

NMPA approval number

国药准字S10850047

Manufacturer

Chinese legal name: 上海生物制品研究所有限责任公司 (domestically manufactured)

Indications

English translation unavailable. The original Chinese source label remains available below.

Dosage and administration

English translation unavailable. The original Chinese source label remains available below.

Adverse reactions

English translation unavailable. The original Chinese source label remains available below.

Contraindications

English translation unavailable. The original Chinese source label remains available below.

Precautions

English translation unavailable. The original Chinese source label remains available below.

Storage

Keep tightly closed.

Specification

English translation unavailable. The original Chinese source label remains available below.

中文说明书原文Original Chinese source label

批准文号

国药准字S10850047

生产企业

上海生物制品研究所有限责任公司(国产)

适应症

A群脑膜炎球菌引起的流行性脑脊髓膜炎

用法用量

1.按标示量(2.5ml)加入稀释剂(注射用磷酸盐缓冲盐水)复溶,摇匀立即使用。|2.于上臂外侧三角肌附着处皮下注射0.5ml(含多糖不低于30μg)。|3.基础免疫注射2针,从6月龄开始,每针间隔3个月;3岁以上儿童只需注射1次。接种应于流行性脑脊髓膜炎流行季节前完成。|根据需要每3年复种1次。在遇有流行情况下,可扩大年龄组做应急接种。

不良反应

本疫苗反应轻微,偶有短暂低热,局部稍有压痛感,可自行缓解。

禁忌

1.有癫痫、惊厥及过敏史者。 |2.患脑部疾患、肾脏病、心脏病及活动性结核者。 |3.患急性传染病及发热者。

注意事项

1.疫苗瓶塞松动者,复溶后有异物或疫苗瓶有裂纹,均不得使用。 |2.疫苗复溶后,应按规定人份(剂量)一次用完,不得分多次使用,剩余的疫苗应废弃。

贮藏

密闭保存。

规格

5ml

证据Evidence

  • 批准文号: 国药准字S10850047
  • rights: 本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据。National Medical Products Administration (China) medicine-registration data.

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.